The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Clover Health Investments Corp (NASDAQ: CLOV) was $2.18 for the day, down -1.36% from the previous closing price of $2.21. In other words, the price has decreased by -$1.36 from its previous closing price. On the day, 10.78 million shares were traded. CLOV stock price reached its highest trading level at $2.215 during the session, while it also had its lowest trading level at $2.12.
Ratios:
Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 07 ’25 when Garipalli Vivek bought 415,000 shares for $2.24 per share. The transaction valued at 929,600 led to the insider holds 1,824,267 shares of the business.
Garipalli Vivek bought 31,980 shares of CLOV for $69,397 on Aug 08 ’25. The Director now owns 1,856,247 shares after completing the transaction at $2.17 per share. On Aug 04 ’25, another insider, Reynoso Jamie L., who serves as the CEO, Medicare Advantage of the company, sold 6,823 shares for $2.89 each. As a result, the insider received 19,718 and left with 3,261,485 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1113461120 and an Enterprise Value of 912188672. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.69 while its Price-to-Book (P/B) ratio in mrq is 3.06. Its current Enterprise Value per Revenue stands at 0.567 whereas that against EBITDA is -22.215.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.00, which has changed by 0.16577542 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is -25.12%, while the 200-Day Moving Average is calculated to be -37.68%.
Shares Statistics:
CLOV traded an average of 9.21M shares per day over the past three months and 10652390 shares per day over the past ten days. A total of 390.25M shares are outstanding, with a floating share count of 382.66M. Insiders hold about 24.83% of the company’s shares, while institutions hold 23.39% stake in the company. Shares short for CLOV as of 1752537600 were 36198932 with a Short Ratio of 3.93, compared to 1749772800 on 22280296. Therefore, it implies a Short% of Shares Outstanding of 36198932 and a Short% of Float of 8.930001.
Earnings Estimates
Current recommendations for the stock of the company come from 1.0 analysts. The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.1 and $0.1 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.19, with 1.0 analysts recommending between $0.19 and $0.19.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $475.4M to a low estimate of $455.43M. As of the current estimate, Clover Health Investments Corp’s year-ago sales were $330.99MFor the next quarter, 4 analysts are estimating revenue of $472.87M. There is a high estimate of $486.6M for the next quarter, whereas the lowest estimate is $460.75M.
A total of 4 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.86B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $1.37BBased on 4 analysts’ estimates, the company’s revenue will be $2.39B in the next fiscal year. The high estimate is $2.6B and the low estimate is $2.25B.
